Filing Details
- Accession Number:
- 0001062993-22-015039
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-06-16 21:50:47
- Reporting Period:
- 2022-06-14
- Accepted Time:
- 2022-06-16 21:50:47
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1621443 | Zynerba Pharmaceuticals Inc. | ZYNE | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1070009 | I Kenneth Moch | C/O Zynerba Pharmaceuticals, Inc. 80 W. Lancaster Avenue, Suite 300 Devon PA 19333 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-06-14 | 23,109 | $0.00 | 28,109 | No | 4 | A | Direct | |
Common Stock | Disposition | 2022-06-14 | 40 | $1.01 | 28,069 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Acquisiton | 2022-06-14 | 34,663 | $0.00 | 34,663 | $1.01 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
34,663 | 2032-06-14 | No | 4 | A | Direct |
Footnotes
- The restricted stock award vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders.
- This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
- The option vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders.